Nucleic acid drug and delivery techniques for disease therapy: Present situation and future prospect DOI Creative Commons
Tianjiao Wang, Youhong Tang,

Yuandong Tao

и другие.

Deleted Journal, Год журнала: 2024, Номер 2(1)

Опубликована: Янв. 1, 2024

Abstract Over the two decades, RNA drugs have gradually made their way from bench to bed. Initially, was not an ideal drug since molecules degrade easily and a relatively short half‐life in circulation system. Nevertheless, chemical modification extended of recent years, which makes new star discovery industry. hold many properties that facilitate application as therapeutic drugs. RNAs could fold form complex conformations bind proteins, small molecules, or other nucleic acids, some even catalytic centers. Protein‐encoding are carriers genetic information DNA ribosomes, various types non‐coding cooperate transcription translation through mechanisms. To date, three mainstream therapies drawn widespread attention: (1) messenger encodes proteins vaccine antigens; (2) interfering RNA, microRNA (miRNA), antisense oligonucleotides inhibit activity pathogenic RNAs; (3) aptamers regulate protein activity. Here, we summarized current research perspectives therapies, may provide innovative highlights for cancer therapy.

Язык: Английский

mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability DOI Creative Commons
Linde Schoenmaker, Dominik Witzigmann, Jayesh A. Kulkarni

и другие.

International Journal of Pharmaceutics, Год журнала: 2021, Номер 601, С. 120586 - 120586

Опубликована: Апрель 8, 2021

A drawback of the current mRNA-lipid nanoparticle (LNP) COVID-19 vaccines is that they have to be stored at (ultra)low temperatures. Understanding root cause instability these may help rationally improve mRNA-LNP product stability and thereby ease temperature conditions for storage. In this review we discuss proposed structures mRNA-LNPs, factors impact strategies optimize stability. Analysis reveals mRNA, ionizable cationic lipid water are present in LNP core. The neutral helper lipids mainly positioned outer, encapsulating, wall. mRNA hydrolysis determining factor instability. It currently unclear how core interacts with what extent degradation prone sites protected through a coat lipids. To vaccines, optimization nucleotide composition should prioritized. Secondly, better understanding milieu exposed LNPs rationalize adjustments structure preserve integrity. Moreover, drying techniques, such as lyophilization, promising options still explored.

Язык: Английский

Процитировано

1067

The role of lipid components in lipid nanoparticles for vaccines and gene therapy DOI

Camilla Hald Albertsen,

Jayesh A. Kulkarni, Dominik Witzigmann

и другие.

Advanced Drug Delivery Reviews, Год журнала: 2022, Номер 188, С. 114416 - 114416

Опубликована: Июль 3, 2022

Язык: Английский

Процитировано

619

On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles DOI Creative Commons
Sean A. Dilliard, Qiang Cheng, Daniel J. Siegwart

и другие.

Proceedings of the National Academy of Sciences, Год журнала: 2021, Номер 118(52)

Опубликована: Дек. 21, 2021

Significance Liver accumulation represents a significant barrier in the development of therapeutically efficacious nanoparticle drug delivery systems. Using series lipid nanoparticles with distinct organ-targeting properties, we provide evidence for plausible mechanism action to non-liver tissues. Following intravenous injection, specific proteins blood are recruited nanoparticle’s surface based on its molecular composition and they endow it unique biological identity that governs ultimate fate body. An innovative paradigm emerges from this mechanistic understanding delivery—endogenous targeting—wherein is rationally engineered interact overcome liver target organs.

Язык: Английский

Процитировано

578

Chemistry of Lipid Nanoparticles for RNA Delivery DOI
Yulia Eygeris, Mohit Gupta, Jeonghwan Kim

и другие.

Accounts of Chemical Research, Год журнала: 2021, Номер 55(1), С. 2 - 12

Опубликована: Дек. 1, 2021

ConspectusLipid nanoparticles (LNPs) are a type of lipid vesicles that possess homogeneous core. These widely used in small-molecule drug and nucleic acid delivery recently gained much attention because their remarkable success as platform for COVID-19 mRNA vaccines. Nonetheless, the utility transient protein expression induced by extends far beyond vaccines against infectious diseases─they also hold promise cancer vaccines, replacement therapies, gene editing components rare genetic diseases. However, naked is inherently unstable prone to rapid degradation nucleases self-hydrolysis. Encapsulation within LNPs protects from extracellular ribonucleases assists with intracellular delivery.In this Account, we discuss core features RNA delivery. We focus our on designed deliver mRNA; however, include examples siRNA-LNP where appropriate highlight commonalities dissimilarities due structure. First, introduce concept LNPs, advantages disadvantages utilizing acids therapeutic agents, general reasoning behind molecular makeup LNPs. briefly most recent clinical successes LNP-based therapies. Second, describe theory methods LNP self-assembly. The common idea all preparation inducing electrostatic interactions between charged lipids promoting nanoparticle growth via hydrophobic interactions. Third, break down composition special fundamental properties purposes each component. This includes identified design criteria, commercial sourcing, impact trafficking, contribution One key ionizable lipids, which initiate binding endosomal membranes facilitate cytosolic release; roles other should not be disregarded, they associated stability, clearance, distribution Fourth, review attributes constructs whole can heavily influence size, charge, internal structure, packing, membrane hydration, affinity toward biomacromolecules. specific techniques examine these how adjusted. Finally, offer perspective future therapies some questions remain realm formulation optimization.

Язык: Английский

Процитировано

508

The dawn of mRNA vaccines: The COVID-19 case DOI Open Access
Rein Verbeke, Ine Lentacker, Stefaan C. De Smedt

и другие.

Journal of Controlled Release, Год журнала: 2021, Номер 333, С. 511 - 520

Опубликована: Март 30, 2021

Язык: Английский

Процитировано

399

Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery DOI Creative Commons
Masatoshi Maeki, Shuya Uno,

Ayuka Niwa

и другие.

Journal of Controlled Release, Год журнала: 2022, Номер 344, С. 80 - 96

Опубликована: Фев. 17, 2022

Язык: Английский

Процитировано

207

Payload distribution and capacity of mRNA lipid nanoparticles DOI Creative Commons
Sixuan Li, Yizong Hu, Andrew Li

и другие.

Nature Communications, Год журнала: 2022, Номер 13(1)

Опубликована: Сен. 23, 2022

Abstract Lipid nanoparticles (LNPs) are effective vehicles to deliver mRNA vaccines and therapeutics. It has been challenging assess packaging characteristics in LNPs, including payload distribution capacity, which critical understanding structure-property-function relationships for further carrier development. Here, we report a method based on the multi-laser cylindrical illumination confocal spectroscopy (CICS) technique examine lipid contents LNP formulations at single-nanoparticle level. By differentiating unencapsulated mRNAs, empty LNPs mRNA-loaded via coincidence analysis of fluorescent tags different components, quantitatively resolving single-mRNA fluorescence, reveal that commonly referenced benchmark formulation using DLin-MC3 as ionizable contains mostly 2 mRNAs per loaded with presence 40%–80% depending assembly conditions. Systematic control variables reveals kinetically controlled mechanism governs capacity LNPs. These results form foundation holistic molecular

Язык: Английский

Процитировано

164

Targeting cancer with mRNA–lipid nanoparticles: key considerations and future prospects DOI Open Access
Edo Kon, Nitay Ad‐El, Inbal Hazan‐Halevy

и другие.

Nature Reviews Clinical Oncology, Год журнала: 2023, Номер 20(11), С. 739 - 754

Опубликована: Авг. 16, 2023

Язык: Английский

Процитировано

144

Extrahepatic targeting of lipid nanoparticles in vivo with intracellular targeting for future nanomedicines DOI Creative Commons
Takashi Nakamura, Yusuke Sato, Yuma Yamada

и другие.

Advanced Drug Delivery Reviews, Год журнала: 2022, Номер 188, С. 114417 - 114417

Опубликована: Июль 3, 2022

Язык: Английский

Процитировано

92

mRNA-based therapeutics: looking beyond COVID-19 vaccines DOI
Hamideh Parhiz, Elena N. Atochina‐Vasserman, Drew Weissman

и другие.

The Lancet, Год журнала: 2024, Номер 403(10432), С. 1192 - 1204

Опубликована: Март 1, 2024

Язык: Английский

Процитировано

82